DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

742 (LIFE): A randomized trial against atenolol. Lancet, 2002,
359:995–1003.
D’Amore A, Black MJ, Thomas WG. The angiotensin II type 2
receptor causes constitutive growth of cardiomyocytes and
does not antagonize angiotensin II type 1 receptor- mediated
hypertrophy. Hypertension, 2005, 46:1347–1354.
Danser AH, Deinum J. Renin, prorenin and the putative
(pro)renin receptor. Hypertension, 2005, 46:1069–1076.
Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and
angiotensins: Uptake from plasma versus in situ synthesis.
Hypertension, 1994, 24:37–48.
de Gasparo M, Catt KJ, Inagami T, et al. International union of
pharmacology: XXIII. The angiotensin II receptors.
Pharmacol Rev, 2000, 52:415–472.
Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting
enzyme–related carboxypeptidase (ACE2) converts
angiotensin I to angiotensin(1–9). Circ Res, 2000, 87:E1–E9.
Epperson S, Gustafsson AB, Gonzalez AM, et al. Pharmacology
of G- protein- linked signaling in cardiac fibroblasts. In:
Villarreal FJ, ed. Interstitial Fibrosis and Heart Failure.
Springer, New York, 2004, pp. 83–97.
EURopean trial On reduction of cardiac events with Perindopril
in stable coronary Artery disease (EUROPA) Investigators.
Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease:
Randomised, double- blind, placebo- controlled, multicentre
trial (the EUROPA study). Lancet, 2003, 362:782–788.
Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory
actions of angiotensin-(1–7). Hypertension, 1997, 30:535–541.
Granger CB, McMurray JJ, Yusuf S, et al., for the CHARM
Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left- ventricular
systolic function intolerant to angiotensin- converting- enzyme
inhibitors: The CHARM- alternative trial. Lancet, 2003,
362:772–776.
Hadjadj S, Belloum R, Bouhanick B, et al. Prognostic value of
angiotensin- I converting enzyme I/D polymorphism for
nephropathy in type 1 diabetes mellitus: A prospective study.
J Am Soc Nephrol, 2001, 12:541–549.
Hansen PB, Hashimoto S, Briggs J, Schnermann J. Attenuated
renovascular constrictor responses to angiotensin II in adenosine
1 receptor knockout mice. Am J Physiol Regul Integr
Comp Physiol, 2003, 285:R44–R49.
Heart Outcomes Prevention Study Investigators. Effects of an
angiotensin- converting- enzyme inhibitor ramipril on cardiovascular
events in high- risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. New Engl J Med,
2000, 342:145–153 (published erratum appears in New Engl J
Med, 2000, 342:478).
Higuchi S, Ohtsu H, Suzuki H, et al. Angiotensin II signal transduction
through the AT1 receptor: Novel insights into mechanisms
and pathophysiology. Clin Sci, 2007, 112:417–428.
Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from
angiotensin II- induced cardiac hypertrophy and fibrosis by
systemic lentiviral delivery of ACE2 in rats. Exp Physiol,
2005, 90:783–790.
Ichihara S, Senbonmatsu T, Price E Jr, et al. Angiotensin II type
2 receptor is essential for left ventricular hypertrophy and cardiac
fibrosis in chronic angiotensin II–induced hypertension.
Circulation, 2001, 104:346–351.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Jones E, Vinh A, McCarthy CA, et al. AT2 receptors: Functional
relevance in cardiovascular disease. Pharmacol Ther, 2008,
120:292–316.
Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive,
angiotensin II- independent glomerulosclerosis in human
(pro)renin receptor-transgenic rats. J Am Soc Nephrol, 2007,
18:1789–1795.
Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression
of cyclooxygenase-2 in the renal cortex of human
prorenin receptor gene- transgenic rats. Kidney Int,
2006,70:641–646.
Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptorindependent
antiinflammatory and angiaggregatory properties
of losartan: Role of the active metabolite EXP3179. Circ Res,
2002, 90:770–776.
Lage SG, Kopel L, Medeiros CCJ, et al. Angiotensin II contributes
to arterial compliance in congestive heart failure. Am
J Physiol Heart Circ Physiol, 2002, 283:H1424–H1429.
Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of
losartan and enalapril on exercise capacity and clinical status
in patients with heart failure. The Losartan Pilot Exercise
Study Investigators. J Am Coll Cardiol, 1997, 30: 983–991.
Levy PJ, Yunis C, Owen J, et al. Inhibition of platelet aggregability
by losartan in essential hypertension. Am J Cardiol,
2000, 86:1188–1192.
Li W, Moore MJ, Vasilieva N, et al. Angiotensin- converting
enzyme 2 is a functional receptor for the SARS coronavirus.
Nature, 2003, 426:450–454.
Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan
to maintain sinus rhythm in patients with long- lasting persistent
atrial fibrillation: A prospective and randomized study.
Circulation, 2002, 106:331–336.
Maggioni AP, Anand I, Gottlieb SO, et al., on behalf of the
ValHeFT Investigators. Effects of valsartan on morbidity and
mortality in patients with heart failure not receiving
angiotensin-converting enzyme inhibitors. J Am Coll Cardiol,
2002, 40:1414–1421.
McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical
considerations of the pharmacology of angiotensin receptor
blockers. J Clin Pharmacol, 1999, 39:547–559.
McMurray JJ, Ostergren J, Swedberg K, et al., for the CHARM
Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left- ventricular
systolic function taking angiotensin- converting- enzyme
inhibitors: The CHARM- added trial. Lancet, 2003, 362:
767–771.
McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct
renin inhibitor aliskiren in patients with symptomatic heart
failure. Circ Heart Fail, 2008, 1:17–24.
Mehta PK, Griendling KK. Angiotensin II cell signaling:
Physiological and pathological effects in the cardiovascular
system. Am J Physiol Cell Physiol, 2007, 292:C82–C97.
Meszaros JG, Gonzalez AM, Endo- Mochizuki Y, et al.
Identification of G protein–coupled signaling pathways in cardiac
fibro-blasts: Cross-talk between G q
and G s
. Am J Physiol,
2000, 278:154–162.
Miura S, Karnik SS, Saku K. Constitutively active homooligomeric
angiotensin II type 2 receptor induces cell signaling
independent of receptor conformation and ligand stimulation.
J Biol Chem, 2005, 280:18237–18244.